Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 1A

CHEMBL214 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:22:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL214
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1A as ChEMBL target CHEMBL214, mapped to UniProt P08908. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 1A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL214
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08908
5-hydroxytryptamine receptor 1A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 1A matters

As of 2026-09-13

5-hydroxytryptamine receptor 1A is reviewed as 5-hydroxytryptamine receptor 1A (UniProt P08908); 5-hydroxytryptamine receptor 1A shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 84 approved drugs, 9808 compounds, and 1664 assays, with lead potency reaching pChEMBL 11.0.

Disease context
major depressive disorder

5-hydroxytryptamine receptor 1A shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ARIPIPRAZOLE, BREXPIPRAZOLE, GEPIRONE HYDROCHLORIDE.

Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include ARIPIPRAZOLE, BREXPIPRAZOLE, GEPIRONE HYDROCHLORIDE, GSK163090. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 84 approved drugs, 9808 compounds, and 1664 assays for this target. The dominant activity type is KI. CHEMBL199824 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL199824 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
84 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1A matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08908, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why major depressive disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9808
Total Compounds
1664
Total Assays
84
Approved Drugs
IC50: 832.0, KI: 6925.0, EC50: 1242.0, KD: 72.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL199824
 11.0 EC50 —
No preferred name
CHEMBL4790600
 11.0 Ki —
No preferred name
CHEMBL4790600
 11.0 EC50 —
No preferred name
CHEMBL4746386
 10.9 Ki —
No preferred name
CHEMBL4757755
 10.9 EC50 —

Approved Drugs

Structure Compound First Approval
GEPIRONE
CHEMBL284092
 2023
LOFEXIDINE
CHEMBL17860
 2018
FLIBANSERIN
CHEMBL231068
 2015
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
 2015
CARIPRAZINE
CHEMBL2028019
 2015
BREXPIPRAZOLE
CHEMBL2105760
 2015
VORTIOXETINE
CHEMBL2104993
 2013
VILAZODONE
CHEMBL439849
 2011
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
LURASIDONE
CHEMBL1237021
 2010
SILODOSIN
CHEMBL24778
 2008
TEGASEROD MALEATE
CHEMBL1516474
 2002
ARIPIPRAZOLE
CHEMBL1112
 2002
FROVATRIPTAN
CHEMBL1279
 2001
APOMORPHINE
CHEMBL53
 2001
ZIPRASIDONE
CHEMBL708
 2001
RIZATRIPTAN
CHEMBL905
 1998
NARATRIPTAN
CHEMBL1278
 1998
ZOLMITRIPTAN
CHEMBL1185
 1997
TAMSULOSIN
CHEMBL836
 1997
QUETIAPINE
CHEMBL716
 1997
MIRTAZAPINE
CHEMBL654
 1996
SERTINDOLE
CHEMBL12713
 1996
OLANZAPINE
CHEMBL715
 1996
NEFAZODONE
CHEMBL623
 1994
CISAPRIDE
CHEMBL1729
 1993
RISPERIDONE
CHEMBL85
 1993
SUMATRIPTAN
CHEMBL128
 1992
EBASTINE
CHEMBL305660
 1990
CLOZAPINE
CHEMBL42
 1989
PERGOLIDE
CHEMBL531
 1988
OXYMETAZOLINE HYDROCHLORIDE
CHEMBL1200791
 1986
BUSPIRONE
CHEMBL49
 1986
PINDOLOL
CHEMBL500
 1982
TRAZODONE
CHEMBL621
 1981
AMOXAPINE
CHEMBL1113
 1980
BROMOCRIPTINE
CHEMBL493
 1978
PROPRANOLOL HYDROCHLORIDE
CHEMBL1671
 1967
METHYSERGIDE MALEATE
CHEMBL1200938
 1962
FLUPHENAZINE
CHEMBL726
 1959
CHLORPROMAZINE
CHEMBL71
 1957
CHLORPROMAZINE HYDROCHLORIDE
CHEMBL1713
 1957
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
 1946
MIANSERIN
CHEMBL6437
 —
FLUMEXADOL
CHEMBL578767
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:22:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL214